Vericel

Vericel(VCEL)

CAMBRIDGE, MA
Biotechnology

Focus: Cellular Therapy

Vericel is a life sciences company focused on Cellular Therapy.

Cell Therapy
Funding Stage
PUBLIC
Employees
1-50
Total Funding
$6.5M
Open Jobs
19

Pipeline & Clinical Trials

Clinical Trials (1)
NCT00140634The Objectives of the Cartilage Repair Registry is to Report Long Term Efficacy and Safety of Cartilage Repair Procedures in Registry Patients
N/A
autologous cultured chondrocytes on porcine collagen membrane
Articular Cartilage Defects
N/A
Clinical Trials (1)
NCT01251588Extension Study for Participants of MACI00206 Study of MACI® for the Treatment of Symptomatic Articular Cartilage Defects of the Knee
N/A
Fracture surgery
Fracture, Ununited
Phase 1/2
Clinical Trials (1)
NCT00424567Feasibility Study of Aastrom Tissue Repair Cells to Treat Non-Union Fractures.
Phase 1/2
Tissue Repair Cells
Alveolar Bone Loss
Phase 1/2
Clinical Trials (1)
NCT00755911Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy
Phase 1/2
Clinical Trials (1)
NCT00797550Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine Fusion
Phase 1/2
Phase 2
Clinical Trials (1)
NCT00468000Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia
Phase 2
Clinical Trials (1)
NCT01670981An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)
Phase 2
Phase 2
Clinical Trials (1)
NCT00765518Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)
Phase 2
Phase 2
Clinical Trials (1)
NCT01020968Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy
Phase 2
autologous cultured chondrocytes on porcine collagen membrane
Articular Cartilage Defect
Phase 3
Clinical Trials (1)
NCT00719576Superiority of MACI® Versus Microfracture Treatment in Patients With Symptomatic Articular Cartilage Defects in the Knee
Phase 3
autologous cultured chondrocytes on porcine collagen membrane
Chondral Defect
Phase 3
Clinical Trials (1)
NCT06915233A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
Phase 3
Phase 3
Clinical Trials (1)
NCT01483898An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)
Phase 3
Ixmyelocel-T
Osteonecrosis
Phase 3
Clinical Trials (1)
NCT00505219Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head
Phase 3
Phase 3
Clinical Trials (1)
NCT03588975A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
Phase 3
Phase 4
Clinical Trials (1)
NCT00158613Study of the Treatment of Articular Repair (STAR)
Phase 4

Open Jobs (19)

Interview Prep Quick Facts
Founded: 2024
Portfolio: 15 clinical trials
Top TAs: Cardiovascular
SEC Filings: 2 available
Open Roles: 19 active jobs
Therapeutic Area Focus
Cardiovascular
3 pipeline
Marketed
Pipeline

Financials (FY2025)

Revenue
$198M20%
R&D Spend
$21M(11%)6%
Net Income
-$3M
Cash
$69M

Hiring Trend

Actively Hiring
19
Open Roles
+19
Added
-0
Filled/Removed

Based on last 2 crawl cycles